Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gentian Diagnostics ASA ( (DE:6FK) ) has shared an update.
Gentian Diagnostics announced that the Japanese Patent Office has granted a notice of allowance for its NT-proBNP diagnostic assay patent, enhancing its intellectual property portfolio in heart failure diagnostics. This patent strengthens Gentian’s competitive position in the third-largest in vitro diagnostics market, Japan, offering significant commercial opportunities and reinforcing its strategic market position globally.
More about Gentian Diagnostics ASA
Gentian Diagnostics, headquartered in Moss, Norway, is a developer and manufacturer of high-quality in vitro diagnostic reagents. The company specializes in immunoassays for infection, inflammation, kidney disease, and heart failure, converting clinically relevant biomarkers to efficient automated analyzers. Gentian serves global human and veterinary diagnostics markets through offices in Sweden, USA, and China.
YTD Price Performance: 21.88%
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: €65.1M
Find detailed analytics on 6FK stock on TipRanks’ Stock Analysis page.